And they're using 25% discount date for their base case plus applying the Phase progression probabilities - they have revenue in the mid-2020's in the billions, so the upside for passing time and hurdles is a multiplier at each Phase completion plus 25% upside per annum. Worth reading through the whole report IMO because all of the calculations and reasoning are fully laid out.
Ann: SRC Approves Commencement Of Fourth And Final Cohort Dosing, page-12
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.0¢ |
Change
-0.015(1.78%) |
Mkt cap ! $102.6M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 85.5¢ | 82.0¢ | $69.84K | 82.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2733 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.5¢ | 3700 | 1 |
View Market Depth
| Last trade - 15.58pm 05/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |